Pembrolizumab in Combination with Radiotherapy for Metastatic Melanoma - Introducing the PERM Trial

K Yip; A Melcher; K Harrington; Timothy Illidge; J Nobes; A Webster; D Smith; Paul Lorigan; P Nathan; J Larkin

doi:10.1016/j.clon.2018.01.001

Pembrolizumab in Combination with Radiotherapy for Metastatic Melanoma - Introducing the PERM Trial

K Yip , A Melcher , K Harrington , Timothy Illidge, J Nobes , A Webster , D Smith , Paul Lorigan, P Nathan , J Larkin

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Review article

Abstract

Single-agent PD-1 inhibitors are the mainstay of systemic treatment for patients with metastatic melanoma. Response rates to single-agent pembrolizumab and nivolumab range from 30 to 45% [1]. Combination treatment, with CTLA-4 and PD-1 inhibitors, improves the response rate to 58%, at the expense of increased treatment-related toxicities, which may be intolerable for some [2]. Hence, a significant proportion of these patients may benefit from different combinations of immune checkpoint modulators and conventional therapies, and the design of these combinations may be guided by understanding the immune microenvironment of the tumour [3].

Original language	English
Journal	Clin Oncol (R Coll Radiol)
Volume	30
Issue number	4
Early online date	2 Feb 2018
DOIs	https://doi.org/10.1016/j.clon.2018.01.001
Publication status	Published - 2018

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clon.2018.01.001

Cite this

@article{f9f9d7cbb4f540fb87daa802e8c1aa73,

title = "Pembrolizumab in Combination with Radiotherapy for Metastatic Melanoma - Introducing the PERM Trial",

abstract = "Single-agent PD-1 inhibitors are the mainstay of systemic treatment for patients with metastatic melanoma. Response rates to single-agent pembrolizumab and nivolumab range from 30 to 45% [1]. Combination treatment, with CTLA-4 and PD-1 inhibitors, improves the response rate to 58%, at the expense of increased treatment-related toxicities, which may be intolerable for some [2]. Hence, a significant proportion of these patients may benefit from different combinations of immune checkpoint modulators and conventional therapies, and the design of these combinations may be guided by understanding the immune microenvironment of the tumour [3].",

author = "K Yip and A Melcher and K Harrington and Timothy Illidge and J Nobes and A Webster and D Smith and Paul Lorigan and P Nathan and J Larkin",

year = "2018",

doi = "10.1016/j.clon.2018.01.001",

language = "English",

volume = "30",

journal = "Clin Oncol (R Coll Radiol)",

issn = "0936-6555",

publisher = "Elsevier BV",

number = "4",

}

TY - JOUR

T1 - Pembrolizumab in Combination with Radiotherapy for Metastatic Melanoma - Introducing the PERM Trial

AU - Yip , K

AU - Melcher , A

AU - Harrington , K

AU - Illidge, Timothy

AU - Nobes , J

AU - Webster , A

AU - Smith , D

AU - Lorigan, Paul

AU - Nathan , P

AU - Larkin , J

PY - 2018

Y1 - 2018

N2 - Single-agent PD-1 inhibitors are the mainstay of systemic treatment for patients with metastatic melanoma. Response rates to single-agent pembrolizumab and nivolumab range from 30 to 45% [1]. Combination treatment, with CTLA-4 and PD-1 inhibitors, improves the response rate to 58%, at the expense of increased treatment-related toxicities, which may be intolerable for some [2]. Hence, a significant proportion of these patients may benefit from different combinations of immune checkpoint modulators and conventional therapies, and the design of these combinations may be guided by understanding the immune microenvironment of the tumour [3].

AB - Single-agent PD-1 inhibitors are the mainstay of systemic treatment for patients with metastatic melanoma. Response rates to single-agent pembrolizumab and nivolumab range from 30 to 45% [1]. Combination treatment, with CTLA-4 and PD-1 inhibitors, improves the response rate to 58%, at the expense of increased treatment-related toxicities, which may be intolerable for some [2]. Hence, a significant proportion of these patients may benefit from different combinations of immune checkpoint modulators and conventional therapies, and the design of these combinations may be guided by understanding the immune microenvironment of the tumour [3].

U2 - 10.1016/j.clon.2018.01.001

DO - 10.1016/j.clon.2018.01.001

M3 - Review article

SN - 0936-6555

VL - 30

JO - Clin Oncol (R Coll Radiol)

JF - Clin Oncol (R Coll Radiol)

IS - 4

ER -

Pembrolizumab in Combination with Radiotherapy for Metastatic Melanoma - Introducing the PERM Trial

Abstract

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Fingerprint

Cite this